An independent review conducted by the Managed Care Services Team of Aon plc has concluded that DarioHealth (NASDAQ: DRIO) could generate significant healthcare cost savings for payers and employers. The review, based on data and studies provided or identified by DarioHealth, found that the company's AI-powered chronic condition management services are associated with estimated annual healthcare cost reductions of 2.5% to 7.2% across a covered population. For a representative population of 20,000 covered lives, that translates to approximately $3.8 million to $10.8 million in annual savings.
Aon also estimated that management of multiple conditions and access to physicians—factors excluded from the initial calculations—could contribute an additional 1.6 to 2.8 percentage points in savings. The review evaluated 17 studies spanning cardiometabolic, musculoskeletal, and behavioral health conditions, including both independently conducted and company-sponsored research. Aon found consistent reported improvements across clinical, behavioral, healthcare utilization, and cost measures, concluding that the evidence supports an association between DarioHealth services and meaningful clinical and financial outcomes.
However, Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. To view the full press release, visit https://ibn.fm/IFvLH.
DarioHealth is an AI-powered healthcare technology company helping health plans, health systems, and employers improve health outcomes while lowering the cost of care. Its integrated platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care to support people living with conditions including diabetes, hypertension, weight management, musculoskeletal, and behavioral health needs. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario's AI platform personalizes care at the individual member level by analyzing biometric, clinical, and behavioral data to deliver more timely and effective interventions. By combining engagement, clinical intelligence, and care delivery within a single platform, Dario helps customers address multiple chronic conditions through one solution.
The latest news and updates relating to DRIO are available in the company's newsroom at https://ibn.fm/DRIO.
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge.
For more information, please visit www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
